RxDoctor Payments Data

Ashok Bhandari, MD

Internal Medicine · Knoxville, TNNPI 1083671648

Payments from drug & device makers

$2,427in general payments, 2019–2025

Across 120 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$590
  • Novo Nordisk$383
  • Bayer$272
  • GSK$266
  • Abbott$183
  • Sanofi-aventis U.S. LLC$136
  • plus $596 from 11 others

What the payments were for

  • Food & beverage$2,40699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,427 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$107,433
Medicare patients
49
Services billed
2,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$107,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$102,469
JardianceEmpagliflozin117$91,184
EliquisApixaban88$79,462
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$37,523
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$36,416
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$34,284
FarxigaDapagliflozin Propanediol39$34,039
GemtesaVibegron57$31,365
XareltoRivaroxaban45$30,923
JanuviaSitagliptin Phosphate44$30,687
Tresiba Flextouch U-100Insulin Degludec18$16,813
MyrbetriqMirabegron26$16,748
Tresiba Flextouch U-200Insulin Degludec14$8,221
Combivent RespimatIpratropium/Albuterol Sulfate13$7,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$383$107,70386 claims
GSKTrelegy Ellipta$266$102,469112 claims
Boehringer IngelheimJardiance, Combivent Respimat$26$98,741130 claims
AstraZenecaBreztri Aerosphere, Farxiga$590$71,56395 claims
Sumitomo Pharma America, Inc.Gemtesa$134$31,36557 claims
Johnson & JohnsonXarelto$97$30,92345 claims
MerckJanuvia$41$30,68744 claims
Astellas Pharma US IncMyrbetriq$78$16,74826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →